Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carmen Tur

Showing results (121-130 of 145) with videos related to

Pageof 15
Sort By:
The Lancet Regional Health. Europe|April 28, 2025
The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational studyCarmen Tur, Pere Carbonell-Mirabent, Susana Otero-Romero, et al.
Annals of Neurology|September 14, 2023
Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple SclerosisJavier Villacieros-Álvarez, Carmen Espejo, Georgina Arrambide, et al.
European Journal of Neurology|July 16, 2025
The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis PatientsAndreu Vilaseca, Elena Urcelay, Sunny Malhotra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2023
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patientsRené Carvajal, Carmen Tur, Xavier Martínez-Gómez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 30, 2026
Optic nerve imaging with OCT predicts disease progression and monitors brain and spinal atrophy in primary progressive multiple sclerosisLuca Bollo, Deborah Pareto, Paula Tagliani, et al.
Brain Communications|July 7, 2025
Deep learning to predict progression independent of relapse activity at a first demyelinating eventLlucia Coll, Deborah Pareto, Francisco Aparicio-Serrano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 29, 2024
Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTsAgustin Pappolla, Cristina Auger, Augusto Sao-Aviles, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2019
The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MSMar Tintore, Georgina Arrambide, Susana Otero-Romero, et al.
JAMA Network Open|April 12, 2024
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With NatalizumabRené Carvajal, Ana Zabalza, Pere Carbonell-Mirabent, et al.
Brain : a Journal of Neurology|June 21, 2022
The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteriaGeorgina Arrambide, Carmen Espejo, Pere Carbonell-Mirabent, et al.
Pageof 15

Showing results (121-130 of 145) with videos related to

Sort By:
Pageof 15
The Lancet Regional Health. Europe|April 28, 2025
The Barcelona baseline risk score to predict long-term prognosis after a first demyelinating event: a prospective observational studyCarmen Tur, Pere Carbonell-Mirabent, Susana Otero-Romero, et al.
Annals of Neurology|September 14, 2023
Myelin Oligodendrocyte Glycoprotein Antibodies in Adults with a First Demyelinating Event Suggestive of Multiple SclerosisJavier Villacieros-Álvarez, Carmen Espejo, Georgina Arrambide, et al.
European Journal of Neurology|July 16, 2025
The Variant rs7665090 Is Associated With Interferon-Beta Response in Multiple Sclerosis PatientsAndreu Vilaseca, Elena Urcelay, Sunny Malhotra, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|September 20, 2023
A single-dose strategy for immunization with live attenuated vaccines is an effective option before treatment initiation in multiple sclerosis patientsRené Carvajal, Carmen Tur, Xavier Martínez-Gómez, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 30, 2026
Optic nerve imaging with OCT predicts disease progression and monitors brain and spinal atrophy in primary progressive multiple sclerosisLuca Bollo, Deborah Pareto, Paula Tagliani, et al.
Brain Communications|July 7, 2025
Deep learning to predict progression independent of relapse activity at a first demyelinating eventLlucia Coll, Deborah Pareto, Francisco Aparicio-Serrano, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 29, 2024
Prediction of disease activity and treatment failure in relapsing-remitting MS patients initiating daily oral DMTsAgustin Pappolla, Cristina Auger, Augusto Sao-Aviles, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 16, 2019
The long-term outcomes of CIS patients in the Barcelona inception cohort: Looking back to recognize aggressive MSMar Tintore, Georgina Arrambide, Susana Otero-Romero, et al.
JAMA Network Open|April 12, 2024
Vaccine Safety and Immunogenicity in Patients With Multiple Sclerosis Treated With NatalizumabRené Carvajal, Ana Zabalza, Pere Carbonell-Mirabent, et al.
Brain : a Journal of Neurology|June 21, 2022
The kappa free light chain index and oligoclonal bands have a similar role in the McDonald criteriaGeorgina Arrambide, Carmen Espejo, Pere Carbonell-Mirabent, et al.
Pageof 15